A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry

Biomedical Chromatography

Volumn 18, Issue 3, 2004, Pages 160-166

  Enz, Albert ^a   Chappuis, Alain ^a   Dattler, Andre ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Carbamate inhibitor; Exelon

Indexed keywords

BIOMOLECULES; BODY FLUIDS; DRUG PRODUCTS; ELECTROSPRAY IONIZATION; MASS SPECTROMETRY; NEURODEGENERATIVE DISEASES; RATS;

ACETYLCHOLINESTERASE; ALZHEIMERS DISEASE; CARBAMATE INHIBITOR; EXELA; RAT PLASMA; RATS BRAIN; REVERSED PHASE LIQUID-CHROMATOGRAPHY; REVERSED-PHASE LIQUID CHROMATOGRAPHY; RIVASTIGMINE; SIMULTANEOUS DETERMINATIONS;

METABOLITES;

3 (1 DIMETHYLAMINOETHYL)PHENOL; 9 (1 DIMETHYLAMINOETHYL) 3 METHYL 3,4,5,6 TETRAHYDROBENZO[G][1,3]OXAZOCIN 2 ONE; ACETIC ACID ETHYL ESTER; ACETONITRILE; ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DRUG METABOLITE; NAP 226 90; NITROGEN; REAGENT; RIVASTIGMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CHEMICAL PROCEDURES; CHOLINESTERASE INHIBITION; CONSTANTS AND COEFFICIENTS; CONTROLLED STUDY; DISSOLUTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG ISOLATION; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION MONITORING; MALE; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; RAT; REVERSED PHASE LIQUID CHROMATOGRAPHY; SEPARATION TECHNIQUE; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

EID: 2342507086     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.304     Document Type: Article

References (10)

1. Amstutz R, Enz A, Marzi M, Boelsterli J and Walkinsha M. Cyclische Phenyl-carbamate des Miotin Typs und ihre Wirkung auf die Acetylcholinesterase. Helvetica Chimica Acta 1990; 73: 739-753.
2. Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, Silman I. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 2002: 41: 3555-3564.
3. Corey-Bloom J, Anand R and Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylocholin-esterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology 1998; 1: 55-65.
4. Cutler NR, Polinsky RJ, Sramek JJ, Enz A, Jhee SS, Mancione L, Hourani J and Zolnouni P. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurologica Scandinavica 1998; 97(4): 244-250.
5. Ellman GL, Courtney D, Andres V, Featherstone RJ. A new rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology 1961; 7: 88-95.
6. Enz A and Floersheim P. Cholinesterase inhibitors: an overview of their mechanisms of action. In Alzheimer Disease: From Molecular Biology to Therapy, Becker R and Giacobini E (eds), Birkhäuser, Boston MA. 1996; 212-215.
7. Enz A, Amstutz R, Boddeke H, Gmelin G and Malanowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Progress in Brain Research 1993; 98: 431-438.
8. Glowinski J and Iversen L. Regional studies of catecholamines in the rat brain. 3. Subcellullar distribution of endogenous and exogenous catecholamines in various brain regions. Biochemical Pharmacology 1966: 15: 977-987.
9. Gottwald MD and Rozanski Rl. Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status. Expert Opinion on Investigative Drugs 1999; 8: 1673-1682.
10. Pommier F and Frigola R. Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectroscopy. Journal of Chromatography B 2003; 784: 301-313.